Latest News

Almirall's sarecycline gains NMPA approval in China, offering a new oral treatment for moderate-to-severe acne, enhancing patient access and outcomes.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

The new therapy targets age-related hair loss with a unique formula, promoting thicker, healthier hair for men over 50.

The new hub for dermatology NPs and PAs offers education, community, and resources to enhance patient care and professional growth.

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

Patient education and partner involvement significantly enhance melanoma detection, especially in underserved and skin-of-color populations, improving survival outcomes.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news on the FDA's breakthrough designation of litifilimab for CLE, data on bitopertin in EPP treatment, the role of icotrokinra in the psoriasis landscape, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.